



Cancer Prevention and Control CIRB Meeting Agenda

September 28, 2023

I. Continuing Review

EAQ191, Cancer Therapy Risk-Reduction with Intensive Systolic BP Management (CARISMA) – a Phase II Study (Version Date 09/14/22)

II. Continuing Review

A191901, Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (Version Date 06/28/22)

III. Continuing Review

A221803, Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial (Version Date 06/30/23)

IV. Initial Re-Review

EA7201, A Phase III Randomized Controlled Trial of Chest CT vs Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma (Version Date 09/11/23)

V. Initial Review

NRG-CC011, Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial (Version Date 07/28/23)

VI. Initial Review

UMI23-13-01, An Early Phase 1 Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (Version Date 08/22/22)

VII. Initial Re-Review

A212101, Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients with Newly Diagnosed Colorectal Cancer (Version Date 08/14/23)

VIII. Amendment Re-Review

EAQ222CD, Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients (Version Date 09/12/23)

IX. Amendment

EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (Version Date 09/05/23)

X. Amendment

MDA21-06-01, A Phase Ib/II Clinical Trial of Nons-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome (Version Date 08/18/23)

XI. Amendment

NRG-CC009, Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (Version Date 08/09/23)

XII. Continuing Review

MDA20-01-01, A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP) (Version Date 05/06/23)

XIII. Continuing Review

URCC-21038, Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting (Version Date 01/11/22)

XIV. Continuing Review

WF-1805CD, Implementation and Effectiveness Trial of HN-STAR (Version Date 01/09/23)
